Login to Your Account

Three Trials Miss Endpoints

Telik's Shares Take Tumble On Telcyta Phase III Failures

By Randall Osborne

Wednesday, December 27, 2006
Analysts pelted Telik Inc. officials with questions they couldn't answer yet during a conference call on preliminary failure data from Phase III trials with the cancer drug Telcyta, and Wall Street smacked down the company's stock by 70.7 percent. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription